PT - JOURNAL ARTICLE AU - TOMOAKI KUROKAWA AU - YOICHI HAMAI AU - MANABU EMI AU - YUTA IBUKI AU - TORU YOSHIKAWA AU - MANATO OHSAWA AU - RYOSUKE HIROHATA AU - MORIHITO OKADA TI - Risk Factors for Recurrence in Esophageal Squamous Cell Carcinoma Without Pathological Complete Response After Trimodal Therapy AID - 10.21873/anticanres.14442 DP - 2020 Aug 01 TA - Anticancer Research PG - 4387--4394 VI - 40 IP - 8 4099 - http://ar.iiarjournals.org/content/40/8/4387.short 4100 - http://ar.iiarjournals.org/content/40/8/4387.full SO - Anticancer Res2020 Aug 01; 40 AB - Background/Aim: Intensive trimodal therapy is needed for locally advanced esophageal squamous cell carcinoma (ESCC). The prediction of recurrence is especially required for patients with pathological residual tumors in the resected primary sites and/or lymph nodes [non-pathological complete response (pCR)] who have a high possibility of recurrence after trimodal therapy. We aimed to determine the risk factors for cancer recurrence in ESCC patients diagnosed with non-pCR after trimodal therapy. Patients and Methods: We evaluated the risk factors for recurrence-free survival (RFS) using the multivariate Cox proportional hazards analysis, based on data from 105 ESCC patients diagnosed with non-pCR after neoadjuvant chemoradiotherapy followed by esophagectomy. Results: Univariate analysis revealed that RFS was significantly associated with postoperative complications, pathological T, N, M stage after therapy (ypT, ypN, ypM), tumor differentiation, lymphovascular invasion (LVI), and pathological response of the primary tumor. Subsequent multivariate analysis revealed postoperative complications ypN, tumor differentiation, and LVI as independent variables for RFS. The RFSs significantly differed between patients with and without these risk factors. Conclusion: Severe postoperative complications, ypN 2/3, poor tumor differentiation, and LVI were significantly associated with poor RFS. These factors may be used as prognostic factors in patients with non-pCR after trimodal therapy.